The first and only treatment for Hypoparathyroidism in adults

The first approved monoclonal antibody specifically inhibiting the signaling of IL-31, a neuroimmune cytokine that drives multiple disease mechanisms in prurigo nodularis

First drug approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas

The first FDA-approved treatment for Niemann-Pick disease type C (NPC)

A novel oral cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults

A first-in-class treatment for adults with pulmonary arterial hypertension (PAH)

The first and only oligonucleotide telomerase inhibitor for LR-MDS patients with transfusion-dependent anemia

First gene therapy to treat patients with sickle cell disease and transfusion-dependent beta thalassemia

For locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC); first approval that includes patients with ROS1-positive NSCLC who have previously received a ROS1 tyrosine kinase inhibitor (TKI)

A new, highly stable macrocyclic gadolinium-based contrast agent (GBCA)

The first and only approved therapeutic for Demodex blepharitis

For the treatment of advanced prostate cancer

An oral mTOR inhibitor used in patients with Tuberous Sclerosis Complex (TSC)

The first and only FDA-approved oral treatment for postpartum depression

The first and only treatment for children and adults with CHAPLE disease

For FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer

The first treatment of fibrodysplasia ossificans progressive (FOP), an ultra-rare bone disease

The first approved treatment for patients with hematologic malignancies in need of an allogeneichematopoietic progenitor cell therapy

The first orally administered fecal microbiota product for the prevention of recurrence of clostridioides difficile infection

A prescription medicine used to delay the onset of Stage 3 type 1 diabetes

An immunomodulator used for the treatment of multiple sclerosis

The first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years.

A topical cream prescribed for plaque psoriasis

The first topical gene therapy for treatment of wounds in patients with dystrophic epidermolysis bullosa

A two-dose anthrax vaccine for post-exposure prophylaxis use

A targeted-chemotherapy drug used to treat certain types of breast and urothelial cancers

The first and only twice-a-year, 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis (MS)

Prescription medication for the treatment of overactive bladder (OAB) in adults

The first and only two-component therapy for eligible adults living with late-onset Pompe Disease

Antimalarial and antirheumatic indicated for the treatment of uncomplicated malaria

First-of-its-kind, selective nematicide that targets plant-parasitic nematodes, yet is gentle on many beneficial organisms in the soil

All-season tire designed for drivers looking for a sensibly luxurious tire that delivers a smooth ride and premium noise comfort

Improve grid resiliency and flexibility with Emerald storage solutions

A fast and easy way to verify the energy origin of low and zero emission products

An exclusive program designed to help contractors manage and grow their business

Herb drops help relieve everyday throat tickles and irritation

Global brand name for picoxystrobin, the active ingredient in more than 15 proven fungicides from Corteva

Light lager with bright aroma and refreshing taste

All-season tire developed for drivers of light trucks, SUVs, and CUVs looking for dependable on-road performance and durability

Ultra-durable exterior coating formulated so dirt washes away upon contact with rain or water for a clean, fresh look

Herbicide combining next-generation corn rootworm protection with the power of the Enlist® weed control system

Enhances the welding process to create stronger, longer-lasting welds

Emerald® Interior and Exterior paints offer revolutionary technology with best-in-class overall performance

Onvansertib - For patients with KRAS/NRAS-mutated metastatic colorectal cancer (mCRC)

For the treatment of cirrhotic Non-Alcoholic Steatohepatitis (NASH) and the reduction in risk of recurrent overt hepatic encephalopathy (OHE)

For adults with Social Anxiety Disorder (SAD)

Committed to helping you get access to Jazz medications and the support you need

Committed to helping patients start on ELAHERE by offering access and reimbursement support, plus affordability assistance

For people living with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN)

Evaluating the safety and efficacy of ELAHERE® compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer

Nirogacestat, an oral small molecule gamma-secretase inhibitor, in patients with progressing desmoid tumors and mirdametinib patients with an inoperable NF1-PN

Evaluating the safety and efficacy of Alpha-1 Antitrypsin for the prevention of Graft-Versus-Host-Disease

Providing with personalized support through every step of the cell therapy journey

A Mitsubishi Power Americas and EES joint venture